BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Zai moves Tesaro's PARP inhibitor into China phase III in first-line ovarian cancer maintenance
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Zai moves Tesaro's PARP inhibitor into China phase III in first-line ovarian cancer maintenance
July 6, 2018
By
Shannon Ellis
No Comments
SHANGHAI – Zai Labs Ltd. has kicked off a phase III China study of ZL-2306 (niraparib), a poly ADP-ribose polymerase (PARP) inhibitor that prolongs the life of women with ovarian cancer.
BioWorld